IL6 and chronic kidney disease: To this end, both healthy human volunteers and subjects with advanced (stage 3–4) CKD were administered SnPP, followed by measurements of plasma IL‐10, IL‐6, as well as anti‐inflammatory TGFβ1 levels (Opal & DePalo, 2000).